GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma

Resectable Pancreatic Cancer Clinical Trial

— NeoPancOne  

Official title:

GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma: A Multicentre Canadian Phase II Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04472910
• Other study ID #: 19-6059
• Status: Active, not recruiting
• Phase: N/A
• Start date: August 21, 2020
• Est. completion date: December 31, 2025

Study information

• Verified date: November 2023
• Source: University Health Network, Toronto
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To date, there have been no Canadian led neoadjuvant or peri-operative trials, this multicentre design gives the opportunity to build more experience with this strategy across Canada in more institutions. The design of this prospective trial will also test our important hypotheses regarding the use of biomarkers to understand the benefit of mFFX in improving outcomes for patients with resectable pancreas cancer. Data from this study would likely inform future studies where patients are given personalised options for the best treatment strategies rather than one empiric approach.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 84
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with a histological diagnosis of PDAC. Those with unconfirmed histology must have this confirmed by EUS-FNB in the pre-screening period prior to commencement of chemotherapy. Invasive PDAC in the setting of intraductal papillary mucinous neoplasm (IPMN) is permitted.

• Patients must consent to EUS-FNB for correlative analysis even if adenocarcinoma has been confirmed, unless confirmation was performed using a previous biopsy or fine needle biopsy with adequate tumour tissue for GATA6 analysis.

• Resectable primary tumour on preoperative biphasic (arterial and venous phases) contrast-enhanced CT for pancreatic staging as per institutional standard of care, with =5 mm slice thickness. MRI for liver metastases (optional) as per institutional standard of care. The definition of resectability (as per NCCN guidelines - see Appendix B) includes:

• no involvement of the celiac artery, common hepatic artery or superior mesenteric artery (or if present a replaced right or common hepatic artery)

• no involvement or <180 (interface between tumour and vessel wall, of the portal vein or superior mesenteric vein, and patent portal vein/splenic vein confluence_

• For tumours of the body and tail of the pancreas, involvement of the splenic artery and vein of any degree is considered resectable disease

• Patients must be medically fit to undergo surgical resection

• No prior oncological treatment for index PDAC

• ECOG Performance status 0-1

• Age > 18 years

• Patients must be medically suitable for treatment with mFFX as per treating medical oncologist

• No evidence of metastases (i.e., metastatic work-up negative including a CT scan of the chest, abdomen (IV and oral contrast, 3 phase) and pelvis)

• Adequate hematologic function

• absolute neutrophil count (ANC) = 1,500 cells/mm3

• platelets = 100 000 cells/mm3

• hemoglobin = 9 g/L (after transfusion is acceptable))

• Creatinine level < 130 µmol/L or CrCl = 50 ml/min

• Patients of child-bearing potential (for female patient: study entry after a menstrual period and a negative pregnancy test) must agree to use two medically acceptable methods of contraception (one for the patient and one for their partner) during the study and for 4 months after the last study treatment intake for women and 6 months for men. These patients must have a pregnancy test repeated every month while on chemotherapy.

• Patients must be able to provide written informed consent

• Adequate liver function (AST <2.5 times the institutional upper limit of normal at the baseline visit, total bilirubin = 2 times the institutional upper limit of normal at the baseline visit)

Exclusion Criteria:

• Patients where attempted EUS-FNB x 2 has not confirmed PDAC in the setting of unconfirmed histology.

• Patients in whom histology has confirmed PDAC but who do not consent to EUS-FNB, unless previous confirmation was by biopsy or fine needle biopsy with adequate tumour tissue for GATA6 analysis.

• Non-ductal pancreas tumours including endocrine tumours, acinar cell carcinoma, cyst adenocarcinoma or ampullary tumours.

• Unresectable PDAC by contrast enhanced CT or MRI. Borderline resectable PDAC (vein and artery) are excluded from this study

• Evidence of metastatic disease

• Prior treatment for index PDAC

• Previous autologous bone marrow transplant or stem cell rescue

• Active hepatitis B or C infection

• Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements

• History of another primary cancer within the last 3 years with the exception of non-melanoma skin cancer, early stage prostate cancer or curatively treated cervical carcinoma in situ or other indolent malignancy (discretion of PI).

• Pregnant or breast-feeding patients are excluded from this study as the chemotherapy agents used in this study have been demonstrated or have the potential to be teratogenic and there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother

• Patients who are being therapeutically anticoagulated with coumadin and cannot have an alternative anticoagulation regimen.

• Known hypersensitivity to any of the drugs used or their components.

• Patients with known complete absence of dihydropyrimidine dehydrogenase (DPD) activity.

• History of QT prolongation or receiving QT prolonging medications.

• History of Gilberts condition

Related Conditions & MeSH terms

• Adenocarcinoma
• Resectable Pancreatic Cancer

Intervention

Drug:
• Modified Folforinox (mFFX)
Neo-adjuvant mFFX for up to 6 cycles, chemo-Adjuvant FFX q 2 weekly or other approach as per investigator to complete up to 6 months chemotherapy

Locations

Country	Name	City	State
Canada	Kingston Health Sciences Centre	Kingston	Ontario
Canada	London Health Sciences Centre	London	Ontario
Canada	Jewish General Hospital	Montréal	Quebec
Canada	Ottawa Hospital	Ottawa	Ontario
Canada	Princess Margaret Cancer Centre	Toronto	Ontario
Canada	Sunnybrook Hospital/Odette Cancer Centre	Toronto	Ontario
Canada	Unity Health (St. Joseph's and St. Michael's)	Toronto	Ontario
Canada	BC Cancer Agency Vancouver	Vancouver	British Columbia

Sponsors (2)

Lead Sponsor	Collaborator
University Health Network, Toronto	Pancreatic Cancer Canada

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess disease free survival (DFS) in resectable PDAC treated with peri-operative mFFX according to baseline GATA6 expression level	Disease free survival	2-4 years
Secondary	Evaluate the feasibility of EUS FNB as an effective modality for the detection of GATA6 expression at first diagnosis, including number of unsuccessful EUS-FNBs.		2-4 years
Secondary	Determine GATA6 in-situ hybridization (ISH)/immunohistochemistry (IHC) success rate		2-4 years
Secondary	Determine GATA6 expression levels in EUS-FNB specimen compared to surgical specimen		2-4 years
Secondary	Determine the DFS according to R0 or R1 resection status		2-4 years
Secondary	Determine the DFS according to baseline Ca19.9 levels		2-4 years
Secondary	Determine the DFS according to modified Moffitt RNA classification		2-4 years
Secondary	To determine the overall response rate (ORR) to neoadjuvant mFFX		2-4 years
Secondary	Determine the percentage of patients who progress on neoadjuvant mFFX		2-4 years
Secondary	Assess pathological response rate to mFFX in the neoadjuvant setting		2-4 years
Secondary	Determine the overall survival (OS) according to GATA6 expression level in the overall population and the GATA6 high/low populations		2-4 years
Secondary	Determine the overall survival (OS) according to R0/R1 resection status in the overall population and the GATA6 high/low populations		2-4 years
Secondary	Determine the overall survival (OS) according to baseline Ca19.9 levels in the overall population and the GATA6 high/low populations		2-4 years
Secondary	Determine the overall survival (OS) according modified Moffitt classification in the overall population and the GATA6 high/low populations		2-4 years